Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XEROCELL study of adipose-derived stromal vascular fraction for autoimmune xerostomia
2023-505149-20-00Phase 2Authorised
- Sponsor
- Assistance Publique-Hôpitaux de Marseille
- Start
- Sep 2024
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous adipose stromal vascular fraction in Sjögren's syndrome, sponsored by Assistance Publique-Hôpitaux de Marseille. Planned start Sep 2024; status: authorised.
02
Drugs
autologous adipose stromal vascular fraction
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on 2023-505149-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505149-20-00.